| Literature DB >> 26170850 |
Meltem Türkay Aydogmus1, Hacer Sebnem Türk1, Sibel Oba1, Oya Gokalp1.
Abstract
INTRODUCTION: In this study, we aimed to determine the appropriate proportion of ketamine-propofol (ketofol), which was prepared in two different proportions for colonoscopy procedures.Entities:
Keywords: colonoscopy; ketamine; ketofol; propofol
Year: 2015 PMID: 26170850 PMCID: PMC4495153 DOI: 10.5114/aoms.2015.52360
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
Mean age, weight, colonoscopy period, gender, ASA score, recovery time, discharge time, additional propofol dose, total propofol dose, colonoscopist and patient satisfaction of the groups
| Parameter | Group 1 ( | Group 2 ( | Value of | |
|---|---|---|---|---|
| Age [years] | 48.85 ±9.96 | 51.08 ±11.76 | 0.364 | |
| Weight [kg] | 74.3 ±15.54 | 76.5 ±14.49 | 0.514 | |
| Colonoscopy period [min] | 13.43 ±4.14 | 13.18 ±6.31 | 0.835 | |
| Gender | Female | 21 (52.50%) | 22 (55.00%) | 0.823 |
| Male | 19 (47.50%) | 18 (45.00%) | ||
| ASA score | 1 | 21 (52.50%) | 17 (42.50%) | 0.370 |
| 2 | 19 (47.50%) | 23 (57.50%) | ||
| Recovery time [min] | 3.75 ±1.98 | 3.38 ±2.26 | 0.433 | |
| Discharge time [min] | 34.73 ±8.13 | 33.03 ±7.05 | 0.321 | |
| Additional propofol dose [mg] | 32.5 ±7.07 | 49.5 ±18.29 | 0.001 | |
| Total propofol dose [mg] | 82.48 ±18.08 | 108.63 ±33.33 | 0.0001 | |
| Colonoscopist satisfaction | 9.6 ±0.67 | 9.25 ±0.87 | 0.047 | |
| Patient satisfaction | 9.63 ±0.63 | 9.38 ±0.77 | 0.117 | |
p < 0.05 (mean ± SD). ASA – American Society of Anesthesiologists.
MAP means of the groups
| Variable | Group 1 ( | Group 2 ( | Value of |
|---|---|---|---|
| Initial | 92.55 ±13.68 | 97.8 ±21.03 | 0.190 |
| 1 min | 86.1 ±14.99 | 84.43 ±19.23 | 0.665 |
| 5 min | 90.23 ±15.13 | 90.75 ±18.44 | 0.890 |
| 10 min | 93.53 ±14.82 | 97.24 ±18.48 | 0.372 |
| 15 min | 91.92 ±14.34 | 92.31 ±15.69 | 0.946 |
| 20 min | 90.33 ±12.5 | 85.71 ±9.9 | 0.546 |
| Value of | 0.548 | 0.001 |
p < 0.05 (mean ± SD). MAP – mean arterial pressure.
PR means of the groups
| Variable | Group 1 ( | Group 2 ( | Value of |
|---|---|---|---|
| Initial | 86.18 ±16.18 | 89.5 ±19.1 | 0.404 |
| 1 min | 87.55 ±13.68 | 89.35 ±13.37 | 0.554 |
| 5 min | 80.93 ±11.26 | 81.8 ±12.45 | 0.743 |
| 10 min | 76.83 ±11.18 | 79.66 ±10.38 | 0.300 |
| 15 min | 76 ±10.03 | 75.94 ±8.88 | 0.986 |
| 20 min | 62.67 ±7.77 | 80.29 ±11.57 | 0.045 |
| Value of | 0.093 | 0.019 |
p < 0.05 (mean ± SD); PR – pulse rate.
Peripheral oxygen saturation means of groups
| Variable | Group 1 ( | Group 2 ( | Value of |
|---|---|---|---|
| Initial | 97.78 ±0.58 | 98 ±0.64 | 0.103 |
| 1 min | 97.93 ±0.47 | 98.08 ±0.47 | 0.161 |
| 5 min | 97.98 ±0.53 | 98.03 ±0.62 | 0.699 |
| 10 min | 98.06 ±0.48 | 98.17 ±0.59 | 0.401 |
| 15 min | 98.08 ±0.28 | 97.94 ±0.68 | 0.495 |
| 20 min | 98.33 ±0.58 | 98.25 ±0.46 | 0.808 |
| Value of | 0.921 | 0.279 |
Ramsey sedation score means of groups
| Variable | Group 1 ( | Group 2 ( | Value of |
|---|---|---|---|
| 1 min | 4.83 ±0.45 | 4.98 ±0.16 | 0.049 |
| 5 min | 4.28 ±0.68 | 3.98 ±0.86 | 0.088 |
| 10 min | 3.44 ±0.77 | 3.52 ±0.79 | 0.709 |
| 15 min | 3.14 ±0.86 | 3.56 ±0.73 | 0.160 |
| 20 min | 3.5 ±1.29 | 3.71 ±0.49 | 0.695 |
| Value of | 0.028 | 0.0001 |
p < 0.05.
Bispectral index means of groups
| Variable | Group 1 ( | Group 2 ( | Value of |
|---|---|---|---|
| Initial | 96.9 ±1.52 | 97.3 ±1.47 | 0.235 |
| 1 min | 51.93 ±11.18 | 47.9 ±6.98 | 0.057 |
| 5 min | 72.85 ±9.71 | 73.03 ±11.55 | 0.942 |
| 10 min | 80.72 ±6.31 | 78.59 ±7.7 | 0.223 |
| 15 min | 86.08 ±6.1 | 77.38 ±7.98 | 0.003 |
| 20 min | 75.43 ±4.86 | 75.43 ±4.86 | 0.999 |
| Value of | 0.0001 | 0.0001 |
p < 0.05.
Occurrence of dreaming and complications in groups
| Variable | Group 1 ( | Group 2 ( | Value of | |||
|---|---|---|---|---|---|---|
| Dreaming | Absent | 25 | 62.50% | 28 | 70.00% | 0.478 |
| Present | 15 | 37.50% | 12 | 30.00% | ||
| Adverse event | Absent | 26 | 65.00% | 39 | 97.50% | 0.0001 |
| Present | 14 | 35.00% | 1 | 2.50% | ||
p < 0.05.
Frequency of adverse events in groups
| Adverse events | Group 1 ( | Group 2 ( | Value of | |||
|---|---|---|---|---|---|---|
| Nausea | Absent | 39 | 97.50% | 40 | 100.00% | 0.999 |
| Present | 1 | 2.50% | 0 | 0.00% | ||
| Vomiting | Absent | 38 | 95.00% | 40 | 100.00% | 0.494 |
| Present | 2 | 5.00% | 0 | 0.00% | ||
| Nausea, vomiting and diplopia | Absent | 40 | 100.00% | 39 | 97.50% | 0.999 |
| Present | 0 | 0.00% | 1 | 2.50% | ||
| Vomiting and vertigo | Absent | 39 | 97.50% | 40 | 100.00% | 0.999 |
| Present | 1 | 2.50% | 0 | 0.00% | ||
| Diplopia | Absent | 39 | 97.50% | 40 | 100.00% | 0.999 |
| Present | 1 | 2.50% | 0 | 0.00% | ||
| Vertigo | Absent | 33 | 82.50% | 40 | 100.00% | 0.011 |
| Present | 7 | 17.50% | 0 | 0.00% | ||
| Vertigo and diplopia | Absent | 38 | 95.00% | 40 | 100.00% | 0.494 |
| Present | 2 | 5.00% | 0 | 0.00% | ||
p < 0.05. Fisher's exact test.